These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

280 related items for PubMed ID: 1523145

  • 1. [Effect of bezafibrate on serum lipid, lipoprotein and apoprotein levels in patients with hyperlipoproteinemia type II and IV].
    Bednarska-Makaruk M, Kuźmińska A, Chotkowska E, Kurjata P, Polakowska M, Broda G, Rywik S.
    Pol Arch Med Wewn; 1992 Mar; 87(3):149-56. PubMed ID: 1523145
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Change in very low-, low-, and high-density lipoproteins during lipid lowering (bezafibrate) therapy: studies in type IIA and type IIb hyperlipoproteinaemia.
    Gavish D, Oschry Y, Fainaru M, Eisenberg S.
    Eur J Clin Invest; 1986 Feb; 16(1):61-8. PubMed ID: 3084275
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Effects of bezafibrate on lipoprotein lipids and apolipoproteins B and A1 in patients with primary hypercholesterolemia].
    Branchi A, Sommariva D, Tirrito M, Bonfiglioli D, Pini C, Scandiani L, Orlandi S, Fasoli A.
    Clin Ter; 1987 Jul 15; 122(1):17-23. PubMed ID: 2973892
    [No Abstract] [Full Text] [Related]

  • 7. [Evaluation of the efficiency of gemfibrozil in treating hyperlipidemia type IIb and IV].
    Polakowska M, Broda G, Rywik S, Piotrowski W, Bednarska M, Kuźmińska A, Pytlak A, Chotkowska E.
    Pol Arch Med Wewn; 1994 Jan 15; 91(1):9-18. PubMed ID: 8190659
    [Abstract] [Full Text] [Related]

  • 8. Abnormalities in very low, low and high density lipoproteins in hypertriglyceridemia. Reversal toward normal with bezafibrate treatment.
    Eisenberg S, Gavish D, Oschry Y, Fainaru M, Deckelbaum RJ.
    J Clin Invest; 1984 Aug 15; 74(2):470-82. PubMed ID: 6378975
    [Abstract] [Full Text] [Related]

  • 9. [Effect of bezafibrate therapy on serum and lipoprotein lipids].
    Romics L, Németh Csóka M, Szám I, Pados G, Karádi I, Köszegi G, Kusztos R.
    Orv Hetil; 1986 Oct 05; 127(40):2425-8, 2431. PubMed ID: 3537905
    [No Abstract] [Full Text] [Related]

  • 10. Effect of bezafibrate treatment on the altered lipoprotein profiles in hypertriglyceridemic subjects.
    Norioka M, Suzuki M, Ryomoto K, Ikebuchi M, Harano Y.
    J Atheroscler Thromb; 2000 Oct 05; 7(4):198-202. PubMed ID: 11521682
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Apolipoprotein A and B (Sf 100-400) metabolism during bezafibrate therapy in hypertriglyceridemic subjects.
    Shepherd J, Packard CJ, Stewart JM, Atmeh RF, Clark RS, Boag DE, Carr K, Lorimer AR, Ballantyne D, Morgan HG.
    J Clin Invest; 1984 Dec 05; 74(6):2164-77. PubMed ID: 6511921
    [Abstract] [Full Text] [Related]

  • 13. Effects of slow-release bezafibrate on serum lipids, lipoproteins, apolipoproteins, and postheparin lipolytic activities in patients with type IV and type V hypertriglyceridemia.
    Saku K, Sasaki J, Arakawa K.
    Clin Ther; 1989 Dec 05; 11(3):331-40. PubMed ID: 2743372
    [Abstract] [Full Text] [Related]

  • 14. [Comparison of the hypolipemic effects of bezafibrate and fenofibrate in patients with hyperlipoproteinemia type II and IV].
    Sznajderman M.
    Przegl Lek; 1984 Dec 05; 41(7):493-9. PubMed ID: 6390536
    [No Abstract] [Full Text] [Related]

  • 15. [Evaluation of apoproteins A and B, lipoproteins and plasma lipids during treatment with bezafibrate in various forms of hyperlipoproteinemia].
    Saitta A, Bonaiuto M, Lanzafame F, Mileto A, Pernice F, Cinquegrani M, Mazza G, Micali G, Pangallo A, Fodale P.
    Clin Ter; 1988 Mar 15; 124(5):373-81. PubMed ID: 2974348
    [No Abstract] [Full Text] [Related]

  • 16. Changes in serum and lipoprotein lipids, and apolipoprotein B and A-I, in patients with different types of primary hyperlipoproteinaemia treated with gemfibrozil.
    Sommariva D, Branchi A, Pini C, Scandiani L, Orlandi S, Fasoli A.
    Int J Clin Pharmacol Res; 1988 Mar 15; 8(5):383-92. PubMed ID: 3068163
    [Abstract] [Full Text] [Related]

  • 17. Changes in lipids and lipoproteins in patients with hyperlipidemia type IIb, IV and V treated with different lipid lowering drugs.
    Hutt V, Wechsler JG, Klör HU, Ditschuneit H.
    Artery; 1980 Mar 15; 8(2):113-9. PubMed ID: 7458676
    [Abstract] [Full Text] [Related]

  • 18. [The therapeutic efficacy of bezafibrate in hyperlipoproteinemias of various types].
    Noseda G, Fragiacomo C, Weidmann P, Bachmann C.
    Schweiz Med Wochenschr; 1980 Dec 06; 110(49):1875-7. PubMed ID: 7455660
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.